Clinical data | |
---|---|
Trade names | Factive |
AHFS/Drugs.com | Monograph |
MedlinePlus | a604014 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 71% |
Protein binding | 60–70% |
Metabolism | Limited metabolism by the liver to minor metabolites |
Excretion | Feces (61%); urine (36%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H20FN5O4 |
Molar mass | 389.387 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Gemifloxacin mesylate, sold under the brand name Factive among others, is a broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is taken by mouth. Vansen Pharma Inc. licensed the active ingredient from LG Life Sciences of Korea.[citation needed]